An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.

NPPA asks cos to revise prices of 17 drugs following BCD exemption: Gireesh Babu, New Delhi Thursday, February 12, 2026, 08:00 Hrs [IST] The National Pharmaceutical Pricing Author ...

Exploring the combination with atezolizumab and radiation therapy Study led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 ...

Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

A comprehensive single-cell atlas of AML uncovers regulatory networks and age-dependent molecular differences to advance the understanding of disease mechanisms and enable subtype-specific therapeutic ...

Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients In this study, we retrospectively classified patients ...

In the Union Budget, custom duty on 17 cancer therapies have been slashed. But, high-cost therapies are still out of reach ...

In the Union Budget, custom duty on 17 cancer therapies have been slashed. But, high-cost therapies are still out of reach for many.